Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2446 to 2460 of 7712 results

  1. Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]

    In development [GID-TA11091] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  2. Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]

    In development [GID-TA11386] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 10 January 2025.

    Technology appraisal guidance
    In consultation

  4. Obinutuzumab for treating lupus nephritis ID6420

    In development [GID-TA11478] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]

    In development [GID-TA11513] Expected publication date: 05 March 2025

    Technology appraisal guidance
    In development

  6. Obesity: clinical assessment and management (QS update)

    In development [GID-QS10183] Expected publication date: TBC

    Quality standard
    In development

  7. Obesity: prevention and lifestyle management (QS update)

    In development [GID-QS10184] Expected publication date: TBC

    Quality standard
    In development

  8. Advanced breast cancer: diagnosis and management (Partial update)

    In development [GID-NG10430] Expected publication date: TBC

    NICE guideline
    In development

  9. Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]

    In development [GID-TA10868] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]

    Awaiting development [GID-TA11216] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]

    Awaiting development [GID-TA11218] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. ABP-654 (ustekinumab biosimilar) for previously treated moderate to severe plaque psoriasis TS ID 11790

      Status ...

    Technology appraisal guidance
    Topic selection

  13. Semaglutide for treating obesity-related heart failure with preserved ejection fraction TS ID 11788

      Status ...

    Technology appraisal guidance
    Topic selection

  14. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

    In development [GID-TA11221] Expected publication date: 26 March 2025

    Technology appraisal guidance
    In development

  15. Polycystic ovary syndrome: diagnosis and management

    In development [GID-NG10436] Expected publication date: TBC

    NICE guideline
    In development